EGF effects on p53 in MDA-468 human breast cancer cells: Implications for G1 arrest

Cell Proliferation

Volumn 30, Issue 2, 1997, Pages 81-94

  Prasad, K A N ^a,b   Church, J G ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PROTEIN P53;

ARTICLE; BREAST CANCER; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PHARMACOLOGY; POINT MUTATION;

EID: 0030882353     PISSN: 09607722     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2184.1997.tb00924.x     Document Type: Article

References (53)

1. ADDISON C, JENKINS JR, STURZBECHER HW. (1990) The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene 5, 423.
2. ARROWSMITH CH, MORIN P. (1996) New insights into p53 function from structural studies. Oncogene 12, 1379.
3. AVILA MA, VELASCO JA, CANSADO J, NOTARIO V. (1994) Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res. 54, 2424.
4. BANKS L, MATLASHEWSKI G, CRAWFORD L. (1986) Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159, 529.
5. BARFORD D. (1991) Molecular mechanisms for the control of enzymic activity by protein phosphorylation. Biochim. Biophys. Acta 1133, 55.
6. BARGONETTI J, FRIEDMAN PN, KERN SE, VOGELSTEIN B, PRIVES C. (1991) Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65, 1083.
7. BARNES DW. (1982) Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J. Cell Biol. 93, 1.
8. BARTEK J, IGGO R, GANNON J, LANE DP. (1990) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5, 893.
9. CASEY G, LO-HSUEH M, LOPEZ ME, VOGELSTEIN B, STANBRIDGE EJ. (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6, 1791.
10. CHURCH JG, BUICK RN. (1988) G-protein-mediated epidermal growth factor signal transduction in a human breast cancer cell line. Evidence for two intracellular pathways distinguishable by pertussis toxin. J. Biol. Chem. 263, 4242.
11. DEPPERT W, BUSCHHAUSEN DG, PATSCHINSKY T, STEINMEYER K. (1990) Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression. Oncogene 5, 1701.
12. FILMUS J, POLLAK MN, CAILLEAU R, BUICK RN. (1985) MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Comm. 128, 898.
13. FILMUS J, TRENT JM, POLLAK MN, BUICK RN. (1987) Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol. Cell Biol. 7, 251.
14. FISCELLA M, ULLRICH SJ, ZAMBRANO N et al. (1993) Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8, 1519.
15. FUNK WD, PAK DT, KARAS RH, WRIGḦT WE, SHAY JW. (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell Biol. 12, 2866.
16. GANNON JV, GREAVES R, IGGO R, LANE DP. (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO. J. 9, 1595.
17. GILL GN, LAZAR CS. (1981) Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 293, 305.
18. GINSBERG D, MECHTA F, YANIV M, OREN M. (1991a) Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88, 9979.
19. GINSBERG D, MICHAEL MD, GINSBERG D, OREN M. (1991b) Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell Biol. 11, 582.
20. HALAZONETIS TD, DAVIS LJ, KANDIL AN. (1993) Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO. J. 12, 1021.
21. HALAZONETIS TD, KANDIL AN. (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO. J. 12, 5057.
22. HARLOW E, CRAWFORD LV, PIM DC, WILLIAMSON NM. (1981) Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39, 861.
23. HARVEY M, SANDS AT, WEISS RS et al. (1993) In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8, 2457.
24. HINDS PW, FINALY CA, QUARTIN RS et al. (1990) Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ. 1, 571.
25. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC. (1991) p53 mutations in human cancers. Science 253, 49.
26. KERN SE, KINZLER KW, BAKER SJ et al. (1991) Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 6, 131.
27. KERN SE, KINZLER KW, BRUSKIN A et al. (1991b) Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708.
28. KUERBITZ SJ, PLUNKETT BS, WALSH WV, KASTAN MB. (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491.
29. LASSAR AB, DAVIS RL, WRIGHT WE et al. (1991) Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66, 305.
30. LEVINE AJ, MOMAND J. (1990) Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim. Biophys. Acta 1032, 119.
31. LEVINE AJ, MOMAND J, FINLAY CA. (1991) The p53 tumour suppressor gene. Nature 351, 453.
32. LIFSHITZ A, LAZAR CS, BUSS JE, GILL GN. (1983) Analysis of morphology and receptor metabolism in clonal variant A431 cells with differing growth responses to epidermal growth factor. J. Cell Physiol. 115, 235.
33. LIN D, SHIELDS MT, ULLRICH SJ, APPELA E, MERCER WE. (1992) Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. USA 89, 9210.
34. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265.
35. MARGOLIS B, RHEE SG, FELDER S et al. (1989) EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling. Cell 57, 1101.
36. MARTINEZ J, GEORGOFF I, MARTINEZ J, LEVINE AJ. (1991) Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5, 151.
37. MICHALOVITZ D, HALEVY O, OREN M. (1991) p53 mutations: gains or losses? J. Cell Biochem. 45, 22.
38. MILNER J. (1984) Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 310, 143.
39. MILNER J. (1991) The role of p53 in the normal control of cell proliferation [published erratum appears in Curr. Opin Cell Biol. 1991 Jun; 3(3): following 574]. Curr Opin Cell Biol 3, 282.
40. MILNER J, COOK A, SHELDON M. (1987) A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene 1, 453.
41. MILNER J, MEDCALF EA. (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765.
42. NIGRO JM, BAKER SJ, PREISINGER AC et al. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705.
43. PRASAD KA, CHURCH JG. (1991) EGF-dependent growth inhibition in MDA-468 human breast cancer cells is characterized by late G1 arrest and altered gene expression [published erratum in Exp. Cell Res. 1991; 196(2): 365]. Exp. Cell Res. 195, 20.
44. PRASAD KA, CHURCH JG. (1997) Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells. Biochem. Biophys. Res. Commun. 232, 14.
45. SHAULSKY G, BEN-ZE'EV A, ROTTER V. (1990) Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5, 1707.
46. SLINGERLAND JM, JENKINS JR, BENCHIMOL S. (1993) The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. Embo. J. 12, 1029.
47. STEINMEYER K, MAACKE H, DEPPERT W. (1990) Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation of p53 expression. Oncogene 5, 1691.
48. TSUKADA T, TOMOOKA Y, TAKAI S et al. (1993) Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8, 3313.
49. ULLRICH SJ, ANDERSON CW, MERCER WE, APPELLA E. (1992) The p53 tumor suppressor protein, a modulator of cell proliferation. J. Biol. Chem. 267, 15 259.
50. ULLRICH SJ, MERCER WE, APPELLA E. (1992) Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene 7, 1635.
51. ULLRICH SJ, SAKAGUCHI K, LEES-MILLER SP et al. (1993) Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. Proc. Natl. Acad. Sci. USA 90, 5954.
52. WANG NP, TO H, LEE WH, LEE EY. (1993) Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 8, 279.
53. ZERRAHN J, DEPPERT W, WEIDEMANN D, PATSCHINSKY T, RICHARDS F, MILER J. (1992) Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7, 1371.